Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for infection-associated thrombocytopenia in ACLF
ChiCTR2600130254Phase 4Not yet recruiting
- Sponsor
- Shandong Public Health Clinical Center
- Start
- Aug 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of recombinant human thrombopoietin in acute-on-chronic liver failure (ACLF) and Thrombocytopenia (2 arms), sponsored by Shandong Public Health Clinical Center. Primary endpoint: Proportion of responders at Day 14. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute-on-chronic liver failure (ACLF)Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600130254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130254.